NewLink Genetics Corporation (NASDAQ:NLNK) has been assigned a $7.00 price target by analysts at Jefferies Group LLC in a research note issued to investors on Friday. The brokerage presently has a “hold” rating on the biotechnology company’s stock. Jefferies Group LLC’s price target points to a potential upside of 5.11% from the stock’s previous close.

NLNK has been the topic of a number of other research reports. Cantor Fitzgerald set a $32.00 price target on NewLink Genetics Corporation and gave the stock a “buy” rating in a research report on Sunday, June 4th. Zacks Investment Research raised NewLink Genetics Corporation from a “sell” rating to a “hold” rating in a research report on Saturday, July 29th. ValuEngine downgraded NewLink Genetics Corporation from a “sell” rating to a “strong sell” rating in a research report on Friday, June 9th. Finally, Robert W. Baird downgraded NewLink Genetics Corporation from an “outperform” rating to a “neutral” rating and decreased their target price for the company from $25.00 to $8.00 in a research report on Thursday, June 8th. One analyst has rated the stock with a sell rating, three have issued a hold rating and three have given a buy rating to the company’s stock. The company has a consensus rating of “Hold” and a consensus price target of $18.17.

NewLink Genetics Corporation (NASDAQ:NLNK) opened at 6.66 on Friday. The firm’s market capitalization is $195.94 million. The firm has a 50 day moving average price of $7.06 and a 200-day moving average price of $13.17. NewLink Genetics Corporation has a 12 month low of $5.90 and a 12 month high of $25.17.

NewLink Genetics Corporation (NASDAQ:NLNK) last announced its quarterly earnings results on Friday, July 28th. The biotechnology company reported ($0.57) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.78) by $0.21. The firm had revenue of $10.37 million for the quarter, compared to the consensus estimate of $2.65 million. NewLink Genetics Corporation had a negative return on equity of 55.03% and a negative net margin of 161.94%. On average, equities analysts forecast that NewLink Genetics Corporation will post ($2.82) EPS for the current year.

COPYRIGHT VIOLATION WARNING: “Jefferies Group LLC Analysts Give NewLink Genetics Corporation (NLNK) a $7.00 Price Target” was originally posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this article on another site, it was copied illegally and reposted in violation of U.S. & international copyright laws. The correct version of this article can be accessed at https://www.thecerbatgem.com/2017/08/26/jefferies-group-llc-analysts-give-newlink-genetics-corporation-nlnk-a-7-00-price-target.html.

Institutional investors have recently bought and sold shares of the stock. State of Wisconsin Investment Board purchased a new position in NewLink Genetics Corporation during the second quarter valued at approximately $125,000. Trexquant Investment LP increased its position in NewLink Genetics Corporation by 39.1% in the second quarter. Trexquant Investment LP now owns 18,132 shares of the biotechnology company’s stock valued at $133,000 after buying an additional 5,097 shares during the last quarter. Advisor Group Inc. increased its position in NewLink Genetics Corporation by 3.4% in the second quarter. Advisor Group Inc. now owns 18,082 shares of the biotechnology company’s stock valued at $133,000 after buying an additional 600 shares during the last quarter. The Manufacturers Life Insurance Company increased its position in NewLink Genetics Corporation by 3.0% in the second quarter. The Manufacturers Life Insurance Company now owns 19,069 shares of the biotechnology company’s stock valued at $140,000 after buying an additional 556 shares during the last quarter. Finally, First Mercantile Trust Co. purchased a new position in NewLink Genetics Corporation during the first quarter valued at approximately $143,000. 51.42% of the stock is currently owned by institutional investors.

About NewLink Genetics Corporation

NewLink Genetics Corporation is a clinical-stage immuno-oncology company focused on discovering, developing and commercializing immunotherapeutic products for the treatment of cancer. The Company’s portfolio includes biologic and small-molecule immunotherapy product candidates for a range of oncology indications.

Analyst Recommendations for NewLink Genetics Corporation (NASDAQ:NLNK)

Receive News & Stock Ratings for NewLink Genetics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NewLink Genetics Corporation and related stocks with our FREE daily email newsletter.